

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
(**深圳市海普瑞藥業集團股份有限公司**)

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
(**Stock code: 9989**)

**DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Wednesday, October 27, 2021 for the purpose of considering and approving the third quarterly results of the Group for the nine months ended September 30, 2021 and its publication.

By Order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
October 15, 2021

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*